Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains
CAG repeat expansion in the Huntington's disease gene (HD) was examined in postmortem brains from 310 clinically diagnosed and 15 ‘at risk’ individuals. Presence of an expanded CAG allele (>37 units) was the cause of the disorder in almost all cases (307 of 310). Despite a diversity of repor...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
1994-12-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996184700192 |
id |
doaj-e9c2806463654e5ca90173fec7656a03 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Francesca Persichetti Jayalakshmi Srinidhi Lisa Kanaley Pei Ge Richard H. Myers Kenneth D'Arrigo Glenn T. Barnes Marcy E. MacDonald Jean-Paul Vonsattel James F. Gusella Edward D. Bird |
spellingShingle |
Francesca Persichetti Jayalakshmi Srinidhi Lisa Kanaley Pei Ge Richard H. Myers Kenneth D'Arrigo Glenn T. Barnes Marcy E. MacDonald Jean-Paul Vonsattel James F. Gusella Edward D. Bird Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains Neurobiology of Disease Huntington's disease mutation neuropathology phenocopy post-mortem brain trinucleotide repeat |
author_facet |
Francesca Persichetti Jayalakshmi Srinidhi Lisa Kanaley Pei Ge Richard H. Myers Kenneth D'Arrigo Glenn T. Barnes Marcy E. MacDonald Jean-Paul Vonsattel James F. Gusella Edward D. Bird |
author_sort |
Francesca Persichetti |
title |
Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains |
title_short |
Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains |
title_full |
Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains |
title_fullStr |
Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains |
title_full_unstemmed |
Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains |
title_sort |
huntington's disease cag trinucleotide repeats in pathologically confirmed post-mortem brains |
publisher |
Elsevier |
series |
Neurobiology of Disease |
issn |
1095-953X |
publishDate |
1994-12-01 |
description |
CAG repeat expansion in the Huntington's disease gene (HD) was examined in postmortem brains from 310 clinically diagnosed and 15 ‘at risk’ individuals. Presence of an expanded CAG allele (>37 units) was the cause of the disorder in almost all cases (307 of 310). Despite a diversity of reporting clinicians, neurological and psychiatric onset and age at death all displayed significant inverse correlations with CAG number indicating that diagnosis of onset is reasonably accurate, and that most patients die from the disease and its complications. Neuronal changes before clinical onset are not detected by conventional microscopic examination as three out of 15 ‘at risk’ brains had an expanded CAG allele but no neuropathology. The cause of HD-like neuropathology in three exceptional brains from clinically diagnosed individuals is unclear. The disorder in these cases could be an HD phenocopy or result from alternative mutational mechanisms at theHDlocus. |
topic |
Huntington's disease mutation neuropathology phenocopy post-mortem brain trinucleotide repeat |
url |
http://www.sciencedirect.com/science/article/pii/S0969996184700192 |
work_keys_str_mv |
AT francescapersichetti huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains AT jayalakshmisrinidhi huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains AT lisakanaley huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains AT peige huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains AT richardhmyers huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains AT kennethdarrigo huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains AT glenntbarnes huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains AT marcyemacdonald huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains AT jeanpaulvonsattel huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains AT jamesfgusella huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains AT edwarddbird huntingtonsdiseasecagtrinucleotiderepeatsinpathologicallyconfirmedpostmortembrains |
_version_ |
1724211505278222336 |
spelling |
doaj-e9c2806463654e5ca90173fec7656a032021-03-20T05:00:06ZengElsevierNeurobiology of Disease1095-953X1994-12-0113159166Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brainsFrancesca Persichetti0Jayalakshmi Srinidhi1Lisa Kanaley2Pei Ge3Richard H. Myers4Kenneth D'Arrigo5Glenn T. Barnes6Marcy E. MacDonald7Jean-Paul Vonsattel8James F. Gusella9Edward D. Bird10Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, MA, 02129; Brain Tissue Resource Center, McLean Hospital, Belmont, MA, 02178; Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown, MA, 02129; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, 02118; Department of Genetics, Harvard Medical School, Boston, MA, 02114, U.S.A.CAG repeat expansion in the Huntington's disease gene (HD) was examined in postmortem brains from 310 clinically diagnosed and 15 ‘at risk’ individuals. Presence of an expanded CAG allele (>37 units) was the cause of the disorder in almost all cases (307 of 310). Despite a diversity of reporting clinicians, neurological and psychiatric onset and age at death all displayed significant inverse correlations with CAG number indicating that diagnosis of onset is reasonably accurate, and that most patients die from the disease and its complications. Neuronal changes before clinical onset are not detected by conventional microscopic examination as three out of 15 ‘at risk’ brains had an expanded CAG allele but no neuropathology. The cause of HD-like neuropathology in three exceptional brains from clinically diagnosed individuals is unclear. The disorder in these cases could be an HD phenocopy or result from alternative mutational mechanisms at theHDlocus.http://www.sciencedirect.com/science/article/pii/S0969996184700192Huntington's diseasemutationneuropathologyphenocopypost-mortem braintrinucleotide repeat |